Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2001

View Archived Issues

New data demonstrate cognitive benefits with quetiapine in treatment-naive schizophrenia patients

Promising results emerge from phase III trial of Pennsaid

Myriad Genetics' MPC-7869 stabilizes PSA levels in phase II

Isis Pharmaceuticals reports Q1 highlights

LEraf-AON, a liposomal antisense oligodeoxyribonucleotide for enhancing radiation effects

SP antagonist CP-96345 inhibits HIV replication in MDMs

New development candidate for human rhinovirus infections: BTA-188

Avelox approved in U.S. for additional antiinfective indication

Synthetic globo H conjugate tested in breast cancer patients

Chrysamine G suppresses Abeta neurotoxicity and may be useful in Alzheimer's disease

Aurora Biosciences obtains license to Microcide bacterial target technology

Novogen creates new company to develop phenoxodiol

Small-molecule dual alphavbeta3/alphavbeta5 integrin inhibitor Sch-221153 inhibits angiogenesis

Tolterodine ER shows improved efficacy and safety

MetaPhore's enzyme mimetic shows potential as stroke treatment in animal model

AxyS receives milestone payment in cathepsin S inhibitor collaboration

Orally active, nonpeptide chymase inhibitor with good potency and selectivity designed at Welfide

Inex and Elan form joint venture to develop and commercialize Onco TCS

ORP150, a novel protein that contributes to neuronal resistance to ischemic stress

CASB6411 polypeptides and polynucleotides and use in cancer treatment, diagnosis

PDH-increasing amides designed at AstraZeneca

Water-soluble prodrug prepared to overcome clinical limitations of quercetin

GlaxoSmithKline early development portfolio includes nonpeptide TPO mimetics

Nonestrogenic steroid sulfatase inhibitors identified at Jenapharm

3-D's new serine protease inhibitors and their use disclosed in recent patent

GABA-A receptor ligands from MS&D useful for anxiety, epilepsy, cognition disorders

Phthalazinones specifically claimed by Byk Gulden for inflammatory airways disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...